Listed

Cumberland Pharmaceuticals Inc

CPIXNasdaqCIK 1087294HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$8.8m, Q2 FY2026
Operating income−$3.2m, Q2 FY2026
Net income−$4.3m, Q2 FY2026
Cumberland Pharmaceuticals Inc, income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m10.1Revenue, Q3 FY2023, three months to 2023-09-30$10.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-07, accession 0001628280-25-011366.Report this figure9.4Revenue, Q4 FY2023, three months to 2023-12-31$9.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-07, accession 0001628280-25-011366.Report this figure8.5Revenue, Q1 FY2024, three months to 2024-03-31$8.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure9.8Revenue, Q2 FY2024, three months to 2024-06-30$9.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure9.1Revenue, Q3 FY2024, three months to 2024-09-30$9.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure10.4Revenue, Q4 FY2024, three months to 2024-12-31$10.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure11.7Revenue, Q1 FY2025, three months to 2025-03-31$11.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure10.8Revenue, Q2 FY2025, three months to 2025-06-30$10.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure8.3Revenue, Q3 FY2025, three months to 2025-09-30$8.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure13.7Revenue, Q4 FY2025, three months to 2025-12-31$13.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure9.1Revenue, Q1 FY2026, three months to 2026-03-31$9.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure8.8Revenue, Q2 FY2026, three months to 2026-06-30$8.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure
Cost of revenue$m1.8Cost of revenue, Q3 FY2023, three months to 2023-09-30$1.8m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2024-11-08, accession 0001628280-24-046730.Report this figure1.5Cost of revenue, Q4 FY2023, three months to 2023-12-31$1.5m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2025-03-07, accession 0001628280-25-011366. Derived: 12-month figure less the 9-month figure.Report this figure1.6Cost of revenue, Q1 FY2024, three months to 2024-03-31$1.6m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-05-09, accession 0001628280-25-024342.Report this figure1.7Cost of revenue, Q2 FY2024, three months to 2024-06-30$1.7m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-08-08, accession 0001628280-25-039326.Report this figure1.3Cost of revenue, Q3 FY2024, three months to 2024-09-30$1.3m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-11-07, accession 0001087294-25-000020.Report this figure2.0Cost of revenue, Q4 FY2024, three months to 2024-12-31$2.0m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2026-03-09, accession 0001087294-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure1.4Cost of revenue, Q1 FY2025, three months to 2025-03-31$1.4m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure2.0Cost of revenue, Q2 FY2025, three months to 2025-06-30$2.0m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-08-08, accession 0001628280-25-039326.Report this figure1.0Cost of revenue, Q3 FY2025, three months to 2025-09-30$988.8k. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-11-07, accession 0001087294-25-000020.Report this figure2.2Cost of revenue, Q4 FY2025, three months to 2025-12-31$2.2m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2026-03-09, accession 0001087294-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure1.9Cost of revenue, Q1 FY2026, three months to 2026-03-31$1.9m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figurenot reported
Research and development$m1.9Research and development, Q3 FY2023, three months to 2023-09-30$1.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-08, accession 0001628280-24-046730.Report this figure1.3Research and development, Q4 FY2023, three months to 2023-12-31$1.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-07, accession 0001628280-25-011366. Derived: 12-month figure less the 9-month figure.Report this figure1.2Research and development, Q1 FY2024, three months to 2024-03-31$1.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-09, accession 0001628280-25-024342.Report this figure1.1Research and development, Q2 FY2024, three months to 2024-06-30$1.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-08, accession 0001628280-25-039326.Report this figure1.3Research and development, Q3 FY2024, three months to 2024-09-30$1.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-07, accession 0001087294-25-000020.Report this figure1.3Research and development, Q4 FY2024, three months to 2024-12-31$1.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-09, accession 0001087294-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure1.3Research and development, Q1 FY2025, three months to 2025-03-31$1.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure0.8Research and development, Q2 FY2025, three months to 2025-06-30$837.4k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure1.3Research and development, Q3 FY2025, three months to 2025-09-30$1.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-07, accession 0001087294-25-000020.Report this figure1.5Research and development, Q4 FY2025, three months to 2025-12-31$1.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-09, accession 0001087294-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure1.5Research and development, Q1 FY2026, three months to 2026-03-31$1.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure0.8Research and development, Q2 FY2026, three months to 2026-06-30$772.2k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure
Operating income$m(1.9)Operating income, Q3 FY2023, three months to 2023-09-30−$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-07, accession 0001628280-25-011366.Report this figure(6.2)Operating income, Q4 FY2023, three months to 2023-12-31−$6.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-07, accession 0001628280-25-011366.Report this figure(1.9)Operating income, Q1 FY2024, three months to 2024-03-31−$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure(1.0)Operating income, Q2 FY2024, three months to 2024-06-30−$1.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure(1.7)Operating income, Q3 FY2024, three months to 2024-09-30−$1.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure(1.8)Operating income, Q4 FY2024, three months to 2024-12-31−$1.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure1.3Operating income, Q1 FY2025, three months to 2025-03-31$1.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure(3.1)Operating income, Q2 FY2025, three months to 2025-06-30−$3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure(2.0)Operating income, Q3 FY2025, three months to 2025-09-30−$2.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure(1.4)Operating income, Q4 FY2025, three months to 2025-12-31−$1.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure(3.1)Operating income, Q1 FY2026, three months to 2026-03-31−$3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure(3.2)Operating income, Q2 FY2026, three months to 2026-06-30−$3.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure
Interest expense$m0.1Interest expense, Q3 FY2023, three months to 2023-09-30$110.1k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-11-08, accession 0001628280-24-046730.Report this figure0.2Interest expense, Q4 FY2023, three months to 2023-12-31$178.8k. XBRL concept us-gaap:InterestExpense. 10-K filed 2025-03-07, accession 0001628280-25-011366. Derived: 12-month figure less the 9-month figure.Report this figure0.1Interest expense, Q1 FY2024, three months to 2024-03-31$118.5k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-05-09, accession 0001628280-25-024342.Report this figure0.1Interest expense, Q2 FY2024, three months to 2024-06-30$126.3k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-08-08, accession 0001628280-25-039326.Report this figure0.1Interest expense, Q3 FY2024, three months to 2024-09-30$137.4k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-11-07, accession 0001087294-25-000020.Report this figure0.2Interest expense, Q4 FY2024, three months to 2024-12-31$223.3k. XBRL concept us-gaap:InterestExpense. 10-K filed 2026-03-09, accession 0001087294-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure0.2Interest expense, Q1 FY2025, three months to 2025-03-31$163.8k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure0.0Interest expense, Q2 FY2025, three months to 2025-06-30$471. XBRL concept us-gaap:InterestExpense. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure0.1Interest expense, Q3 FY2025, three months to 2025-09-30$109.7k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-11-07, accession 0001087294-25-000020.Report this figure0.1Interest expense, Q4 FY2025, three months to 2025-12-31$112.9k. XBRL concept us-gaap:InterestExpense. 10-K filed 2026-03-09, accession 0001087294-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure0.1Interest expense, Q1 FY2026, three months to 2026-03-31$85.8k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure0.0Interest expense, Q2 FY2026, three months to 2026-06-30$724. XBRL concept us-gaap:InterestExpense. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$6.9k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-08, accession 0001628280-24-046730.Report this figure0.0Income tax, Q4 FY2023, three months to 2023-12-31$25.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-03-07, accession 0001628280-25-011366. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2024, three months to 2024-03-31$11.4k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-09, accession 0001628280-25-024342.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-06-30$11.4k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-08, accession 0001628280-25-039326.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$11.4k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-07, accession 0001087294-25-000020.Report this figure(0.1)Income tax, Q4 FY2024, three months to 2024-12-31−$57.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-09, accession 0001087294-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$5.7k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$5.7k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-09-30$5.7k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-07, accession 0001087294-25-000020.Report this figure0.0Income tax, Q4 FY2025, three months to 2025-12-31$23.2k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-09, accession 0001087294-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$3.9k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$3.9k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure
Net income$m(1.0)Net income, Q3 FY2023, three months to 2023-09-30−$1.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-07, accession 0001628280-25-011366.Report this figure(6.3)Net income, Q4 FY2023, three months to 2023-12-31−$6.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-07, accession 0001628280-25-011366.Report this figure(1.9)Net income, Q1 FY2024, three months to 2024-03-31−$1.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure(1.1)Net income, Q2 FY2024, three months to 2024-06-30−$1.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure(1.5)Net income, Q3 FY2024, three months to 2024-09-30−$1.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure(1.9)Net income, Q4 FY2024, three months to 2024-12-31−$1.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure1.3Net income, Q1 FY2025, three months to 2025-03-31$1.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure(0.7)Net income, Q2 FY2025, three months to 2025-06-30−$740.7k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure(1.9)Net income, Q3 FY2025, three months to 2025-09-30−$1.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure(1.4)Net income, Q4 FY2025, three months to 2025-12-31−$1.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure(3.3)Net income, Q1 FY2026, three months to 2026-03-31−$3.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure(4.3)Net income, Q2 FY2026, three months to 2026-06-30−$4.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure
Diluted EPS$ per share(0.07)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-08, accession 0001628280-24-046730.Report this figure(0.44)Diluted EPS, Q4 FY2023, three months to 2023-12-31−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-13, accession 0001628280-24-010725.Report this figure(0.14)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-09, accession 0001628280-25-024342.Report this figure(0.08)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-08, accession 0001628280-25-039326.Report this figure(0.11)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-07, accession 0001087294-25-000020.Report this figure(0.14)Diluted EPS, Q4 FY2024, three months to 2024-12-31−$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-07, accession 0001628280-25-011366.Report this figure0.08Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure(0.05)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure(0.13)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure(0.09)Diluted EPS, Q4 FY2025, three months to 2025-12-31−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure(0.22)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure(0.29)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure
Basic EPS$ per share(0.07)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-08, accession 0001628280-24-046730.Report this figure(0.44)Basic EPS, Q4 FY2023, three months to 2023-12-31−$0.44 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-K filed 2024-03-13, accession 0001628280-24-010725.Report this figure(0.14)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.14 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-09, accession 0001628280-25-024342.Report this figure(0.08)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-08, accession 0001628280-25-039326.Report this figure(0.11)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-07, accession 0001087294-25-000020.Report this figure(0.14)Basic EPS, Q4 FY2024, three months to 2024-12-31−$0.14 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-K filed 2025-03-07, accession 0001628280-25-011366.Report this figure0.08Basic EPS, Q1 FY2025, three months to 2025-03-31$0.08 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure(0.05)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.05 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure(0.13)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure(0.09)Basic EPS, Q4 FY2025, three months to 2025-12-31−$0.09 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure(0.22)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.22 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure(0.29)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.29 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure

Balance sheet

Cash and equivalents$3.9m, Q2 FY2026
Shareholders' equity$17.4m, Q2 FY2026
Cumberland Pharmaceuticals Inc, balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m18.5Cash and equivalents, Q3 FY2023, at 2023-09-30$18.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-13, accession 0001628280-23-038418.Report this figure18.3Cash and equivalents, FY2023, at 2023-12-31$18.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-07, accession 0001628280-25-011366.Report this figure18.5Cash and equivalents, Q1 FY2024, at 2024-03-31$18.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-10, accession 0001628280-24-022658.Report this figure17.3Cash and equivalents, Q2 FY2024, at 2024-06-30$17.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-09, accession 0001628280-24-036529.Report this figure17.5Cash and equivalents, Q3 FY2024, at 2024-09-30$17.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-08, accession 0001628280-24-046730.Report this figure18.0Cash and equivalents, FY2024, at 2024-12-31$18.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure15.1Cash and equivalents, Q1 FY2025, at 2025-03-31$15.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-09, accession 0001628280-25-024342.Report this figure16.1Cash and equivalents, Q2 FY2025, at 2025-06-30$16.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-08, accession 0001628280-25-039326.Report this figure15.2Cash and equivalents, Q3 FY2025, at 2025-09-30$15.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-07, accession 0001087294-25-000020.Report this figure11.4Cash and equivalents, FY2025, at 2025-12-31$11.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure11.0Cash and equivalents, Q1 FY2026, at 2026-03-31$11.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure3.9Cash and equivalents, Q2 FY2026, at 2026-06-30$3.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure
Current assets$m41.8Current assets, Q3 FY2023, at 2023-09-30$41.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-13, accession 0001628280-23-038418.Report this figure35.7Current assets, FY2023, at 2023-12-31$35.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-07, accession 0001628280-25-011366.Report this figure36.2Current assets, Q1 FY2024, at 2024-03-31$36.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-10, accession 0001628280-24-022658.Report this figure35.6Current assets, Q2 FY2024, at 2024-06-30$35.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-09, accession 0001628280-24-036529.Report this figure35.2Current assets, Q3 FY2024, at 2024-09-30$35.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-08, accession 0001628280-24-046730.Report this figure36.5Current assets, FY2024, at 2024-12-31$36.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure31.9Current assets, Q1 FY2025, at 2025-03-31$31.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-09, accession 0001628280-25-024342.Report this figure31.2Current assets, Q2 FY2025, at 2025-06-30$31.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-08, accession 0001628280-25-039326.Report this figure29.9Current assets, Q3 FY2025, at 2025-09-30$29.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-07, accession 0001087294-25-000020.Report this figure37.1Current assets, FY2025, at 2025-12-31$37.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure32.8Current assets, Q1 FY2026, at 2026-03-31$32.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure33.6Current assets, Q2 FY2026, at 2026-06-30$33.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure
Total assets$m87.8Total assets, Q3 FY2023, at 2023-09-30$87.8m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-13, accession 0001628280-23-038418.Report this figure81.8Total assets, FY2023, at 2023-12-31$81.8m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-07, accession 0001628280-25-011366.Report this figure81.5Total assets, Q1 FY2024, at 2024-03-31$81.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-10, accession 0001628280-24-022658.Report this figure78.5Total assets, Q2 FY2024, at 2024-06-30$78.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-09, accession 0001628280-24-036529.Report this figure76.7Total assets, Q3 FY2024, at 2024-09-30$76.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-08, accession 0001628280-24-046730.Report this figure75.6Total assets, FY2024, at 2024-12-31$75.6m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure69.9Total assets, Q1 FY2025, at 2025-03-31$69.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-09, accession 0001628280-25-024342.Report this figure67.9Total assets, Q2 FY2025, at 2025-06-30$67.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-08, accession 0001628280-25-039326.Report this figure65.9Total assets, Q3 FY2025, at 2025-09-30$65.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-07, accession 0001087294-25-000020.Report this figure76.8Total assets, FY2025, at 2025-12-31$76.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure71.0Total assets, Q1 FY2026, at 2026-03-31$71.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure62.9Total assets, Q2 FY2026, at 2026-06-30$62.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure
Current liabilities$m27.3Current liabilities, Q3 FY2023, at 2023-09-30$27.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-13, accession 0001628280-23-038418.Report this figure28.0Current liabilities, FY2023, at 2023-12-31$28.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-07, accession 0001628280-25-011366.Report this figure26.4Current liabilities, Q1 FY2024, at 2024-03-31$26.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-10, accession 0001628280-24-022658.Report this figure24.8Current liabilities, Q2 FY2024, at 2024-06-30$24.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-09, accession 0001628280-24-036529.Report this figure31.1Current liabilities, Q3 FY2024, at 2024-09-30$31.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-08, accession 0001628280-24-046730.Report this figure31.6Current liabilities, FY2024, at 2024-12-31$31.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure25.5Current liabilities, Q1 FY2025, at 2025-03-31$25.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-09, accession 0001628280-25-024342.Report this figure24.0Current liabilities, Q2 FY2025, at 2025-06-30$24.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-08, accession 0001628280-25-039326.Report this figure24.3Current liabilities, Q3 FY2025, at 2025-09-30$24.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-07, accession 0001087294-25-000020.Report this figure36.7Current liabilities, FY2025, at 2025-12-31$36.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure34.5Current liabilities, Q1 FY2026, at 2026-03-31$34.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure35.2Current liabilities, Q2 FY2026, at 2026-06-30$35.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure
Total liabilities$m52.1Total liabilities, Q3 FY2023, at 2023-09-30$52.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-13, accession 0001628280-23-038418.Report this figure52.5Total liabilities, FY2023, at 2023-12-31$52.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-07, accession 0001628280-25-011366.Report this figure54.3Total liabilities, Q1 FY2024, at 2024-03-31$54.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-10, accession 0001628280-24-022658.Report this figure52.5Total liabilities, Q2 FY2024, at 2024-06-30$52.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-09, accession 0001628280-24-036529.Report this figure52.3Total liabilities, Q3 FY2024, at 2024-09-30$52.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-08, accession 0001628280-24-046730.Report this figure53.0Total liabilities, FY2024, at 2024-12-31$53.0m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure41.6Total liabilities, Q1 FY2025, at 2025-03-31$41.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-09, accession 0001628280-25-024342.Report this figure40.2Total liabilities, Q2 FY2025, at 2025-06-30$40.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-08, accession 0001628280-25-039326.Report this figure40.1Total liabilities, Q3 FY2025, at 2025-09-30$40.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-07, accession 0001087294-25-000020.Report this figure52.3Total liabilities, FY2025, at 2025-12-31$52.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure49.7Total liabilities, Q1 FY2026, at 2026-03-31$49.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure45.8Total liabilities, Q2 FY2026, at 2026-06-30$45.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure
Current portion of debt$mnot reported0.0Current portion of debt, FY2023, at 2023-12-31$0. XBRL concept us-gaap:LongTermDebtCurrent. 10-K filed 2025-03-07, accession 0001628280-25-011366.Report this figurenot reportednot reportednot reported5.1Current portion of debt, FY2024, at 2024-12-31$5.1m. XBRL concept us-gaap:LongTermDebtCurrent. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figurenot reportednot reportednot reported0.0Current portion of debt, FY2025, at 2025-12-31$0. XBRL concept us-gaap:LongTermDebtCurrent. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figurenot reportednot reported
Shareholders' equity$m36.0Shareholders' equity, Q3 FY2023, at 2023-09-30$36.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2023-11-13, accession 0001628280-23-038418.Report this figure29.6Shareholders' equity, FY2023, at 2023-12-31$29.6m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2025-03-07, accession 0001628280-25-011366.Report this figure27.5Shareholders' equity, Q1 FY2024, at 2024-03-31$27.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-05-10, accession 0001628280-24-022658.Report this figure26.3Shareholders' equity, Q2 FY2024, at 2024-06-30$26.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-08-09, accession 0001628280-24-036529.Report this figure24.8Shareholders' equity, Q3 FY2024, at 2024-09-30$24.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-08, accession 0001628280-24-046730.Report this figure22.9Shareholders' equity, FY2024, at 2024-12-31$22.9m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-09, accession 0001087294-26-000020.Report this figure28.7Shareholders' equity, Q1 FY2025, at 2025-03-31$28.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-05-09, accession 0001628280-25-024342.Report this figure28.0Shareholders' equity, Q2 FY2025, at 2025-06-30$28.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-08, accession 0001628280-25-039326.Report this figure26.1Shareholders' equity, Q3 FY2025, at 2025-09-30$26.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-07, accession 0001087294-25-000020.Report this figure24.9Shareholders' equity, FY2025, at 2025-12-31$24.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure21.6Shareholders' equity, Q1 FY2026, at 2026-03-31$21.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure17.4Shareholders' equity, Q2 FY2026, at 2026-06-30$17.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure

Cash flow

Operating cash flow$168.7k, Q2 FY2026
Capital expenditure$38.3k, Q2 FY2026
Share repurchases$0, Q2 FY2026
Cumberland Pharmaceuticals Inc, cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k1,237Operating cash flow, Q3 FY2023, three months to 2023-09-30$1.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-08, accession 0001628280-24-046730. Derived: 9-month figure less the 6-month figure.Report this figure1,040Operating cash flow, Q4 FY2023, three months to 2023-12-31$1.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-07, accession 0001628280-25-011366. Derived: 12-month figure less the 9-month figure.Report this figure(2,137)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$2.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-09, accession 0001628280-25-024342.Report this figure(856)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$855.7k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-08, accession 0001628280-25-039326. Derived: 6-month figure less the 3-month figure.Report this figure476Operating cash flow, Q3 FY2024, three months to 2024-09-30$475.5k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-07, accession 0001087294-25-000020. Derived: 9-month figure less the 6-month figure.Report this figure1,905Operating cash flow, Q4 FY2024, three months to 2024-12-31$1.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-09, accession 0001087294-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure3,899Operating cash flow, Q1 FY2025, three months to 2025-03-31$3.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure844Operating cash flow, Q2 FY2025, three months to 2025-06-30$843.8k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-07, accession 0001087294-26-000062. Derived: 6-month figure less the 3-month figure.Report this figure187Operating cash flow, Q3 FY2025, three months to 2025-09-30$187.2k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-07, accession 0001087294-25-000020. Derived: 9-month figure less the 6-month figure.Report this figure3.0Operating cash flow, Q4 FY2025, three months to 2025-12-31$3.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-09, accession 0001087294-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure387Operating cash flow, Q1 FY2026, three months to 2026-03-31$387.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure169Operating cash flow, Q2 FY2026, three months to 2026-06-30$168.7k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-07, accession 0001087294-26-000062. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$k53.1Capital expenditure, Q3 FY2023, three months to 2023-09-30$53.1k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-08, accession 0001628280-24-046730. Derived: 9-month figure less the 6-month figure.Report this figure48.7Capital expenditure, Q4 FY2023, three months to 2023-12-31$48.7k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-07, accession 0001628280-25-011366. Derived: 12-month figure less the 9-month figure.Report this figure41.6Capital expenditure, Q1 FY2024, three months to 2024-03-31$41.6k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-09, accession 0001628280-25-024342.Report this figure7.2Capital expenditure, Q2 FY2024, three months to 2024-06-30$7.2k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-08, accession 0001628280-25-039326. Derived: 6-month figure less the 3-month figure.Report this figure15.4Capital expenditure, Q3 FY2024, three months to 2024-09-30$15.4k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-07, accession 0001087294-25-000020. Derived: 9-month figure less the 6-month figure.Report this figure2.3Capital expenditure, Q4 FY2024, three months to 2024-12-31$2.3k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-09, accession 0001087294-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure47.6Capital expenditure, Q1 FY2025, three months to 2025-03-31$47.6k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure26.5Capital expenditure, Q2 FY2025, three months to 2025-06-30$26.5k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-07, accession 0001087294-26-000062. Derived: 6-month figure less the 3-month figure.Report this figure23.8Capital expenditure, Q3 FY2025, three months to 2025-09-30$23.8k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-07, accession 0001087294-25-000020. Derived: 9-month figure less the 6-month figure.Report this figure(0.0)Capital expenditure, Q4 FY2025, three months to 2025-12-31−$1. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-09, accession 0001087294-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure38.3Capital expenditure, Q2 FY2026, three months to 2026-06-30$38.3k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-07, accession 0001087294-26-000062. Derived: 6-month figure less the 3-month figure.Report this figure
Share repurchases$k202Share repurchases, Q3 FY2023, three months to 2023-09-30$201.7k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2024-11-08, accession 0001628280-24-046730. Derived: 9-month figure less the 6-month figure.Report this figure189Share repurchases, Q4 FY2023, three months to 2023-12-31$189.0k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-K filed 2025-03-07, accession 0001628280-25-011366. Derived: 12-month figure less the 9-month figure.Report this figure248Share repurchases, Q1 FY2024, three months to 2024-03-31$247.6k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2025-05-09, accession 0001628280-25-024342.Report this figure134Share repurchases, Q2 FY2024, three months to 2024-06-30$134.2k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2025-08-08, accession 0001628280-25-039326. Derived: 6-month figure less the 3-month figure.Report this figure98.8Share repurchases, Q3 FY2024, three months to 2024-09-30$98.8k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2025-11-07, accession 0001087294-25-000020. Derived: 9-month figure less the 6-month figure.Report this figure98.4Share repurchases, Q4 FY2024, three months to 2024-12-31$98.4k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-K filed 2026-03-09, accession 0001087294-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure246Share repurchases, Q1 FY2025, three months to 2025-03-31$245.9k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure7.2Share repurchases, Q2 FY2025, three months to 2025-06-30$7.2k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2026-08-07, accession 0001087294-26-000062. Derived: 6-month figure less the 3-month figure.Report this figure10.4Share repurchases, Q3 FY2025, three months to 2025-09-30$10.4k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2025-11-07, accession 0001087294-25-000020. Derived: 9-month figure less the 6-month figure.Report this figure0.0Share repurchases, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-K filed 2026-03-09, accession 0001087294-26-000020. Derived: 12-month figure less the 9-month figure.Report this figure61.0Share repurchases, Q1 FY2026, three months to 2026-03-31$61.0k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure0.0Share repurchases, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2026-08-07, accession 0001087294-26-000062. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)14.98m, Q2 FY2026
Cumberland Pharmaceuticals Inc, shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares14.5Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3014,477,478 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-13, accession 0001628280-23-038418.Report this figure14.6Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3114,587,843 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-10, accession 0001628280-24-022658.Report this figure14.6Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3014,554,264 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-09, accession 0001628280-24-036529.Report this figure14.3Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3014,277,229 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-08, accession 0001628280-24-046730.Report this figure14.1Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3114,098,022 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-09, accession 0001628280-25-024342.Report this figure14.1Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3014,118,091 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-08, accession 0001628280-25-039326.Report this figure14.1Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3014,052,754 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-07, accession 0001087294-25-000020.Report this figure15.3Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3115,259,824 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure15.0Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3014,960,596 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure15.0Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3014,958,534 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-07, accession 0001087294-25-000020.Report this figure15.0Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3114,960,210 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-08, accession 0001087294-26-000049.Report this figure15.0Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3014,981,607 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure

Shares outstanding: 14.98mShares outstanding, period not labelled, at 2026-08-0514,983,107 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-07, accession 0001087294-26-000062.Report this figure at Aug 5, 2026, from the cover of the 10-Q filed Aug 7, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. Listed shows no prices and gives no investment advice.